To include your compound in the COVID-19 Resource Center, submit it here.

Reolysin: Completed Phase II enrollment

Oncolytics said the Gynecologic Oncology Group (GOG) completed enrollment of about 150 patients in an open-label, U.S. Phase II

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE